CBIO NASDAQ

Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.01 (down more than 99.9%), Crescent Biopharma, Inc. would be worth roughly what it owes.
Total debt $1.4M against a stock market value of $474.0M.
Distance to default 7.80 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $718K (short-term plus half of long-term), stock volatility 79.8%; Altman Z'' 4.63. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.